Heidi Pelemans

Anti-HIV and Anti-HBV Activity and Resistance Profile of 2′,3′-Dideoxy-3′-Thiacytidine (3TC) and Its Arylphosphoramidate Derivative CF 1109

Jan Balzarini, Orson Wedgwood, J. Kruining et al. · Biochemical and Biophysical Research Communications · 1996 · 60 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Identification of a Putative Binding Site for [2‘,5‘-Bis-<i>O</i>-(<i>tert</i>-butyldimethylsilyl)-β-<scp>d</scp>-ribofuranosyl]-3‘-spiro-5‘ ‘-(4‘ ‘-amino-1‘ ‘,2‘ ‘-oxathiole-2‘ ‘,2‘ ‘-dioxide)thymine (TSAO) Derivatives at the p51−p66 Interface of HIV-1 Reverse Transcriptase

Fátima Rodríguez‐Barrios, Carlos A. Perez, Esther Lobatón et al. · Journal of Medicinal Chemistry · 2001 · 56 citations · Full text

Life Sciences, Biology, Molecular Biology +17

Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.

Jan Balzarini, Heidi Pelemans, Stefano Aquaro et al. · Molecular Pharmacology · 1996 · 52 citations

Life Sciences, Medicinal Chemistry, Pharmacology +17

Mutational Analysis of Trp-229 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Identifies This Amino Acid Residue as a Prime Target for the Rational Design of New Non-Nucleoside RT Inhibitors

Heidi Pelemans, Robert Esnouf, Erik De Clercq et al. · Molecular Pharmacology · 2000 · 51 citations

Life Sciences, Genetics, Molecular Biology +17

<b>Short Communication</b> : A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures with the Nonnucleoside Reverse Transcriptase Inhibitor Thiocarboxanilide UC-781

Jan Balzarini, Heidi Pelemans, Robert Esnouf et al. · AIDS Research and Human Retroviruses · 1998 · 43 citations

Life Sciences, Infectious Diseases, Infectious Disease Pharmacotherapy +16